These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 17690708

  • 1. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S, Demetri G, Sargent W, Raymond E.
    Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 3. The potential of sunitinib as a therapy in ovarian cancer.
    Leone Roberti Maggiore U, Valenzano Menada M, Venturini PL, Ferrero S.
    Expert Opin Investig Drugs; 2013 Dec 01; 22(12):1671-86. PubMed ID: 24070205
    [Abstract] [Full Text] [Related]

  • 4. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC, Pulido EG, Guillén-Ponce C.
    Anticancer Drugs; 2010 Jan 01; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib.
    Rini BI.
    Expert Opin Pharmacother; 2007 Oct 01; 8(14):2359-69. PubMed ID: 17927489
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib malate.
    Izzedine H, Buhaescu I, Rixe O, Deray G.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):357-64. PubMed ID: 17136543
    [Abstract] [Full Text] [Related]

  • 7. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E.
    Expert Opin Drug Metab Toxicol; 2010 Aug 01; 6(8):1005-15. PubMed ID: 20636223
    [Abstract] [Full Text] [Related]

  • 8. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Christensen JG.
    Ann Oncol; 2007 Sep 01; 18 Suppl 10():x3-10. PubMed ID: 17761721
    [Abstract] [Full Text] [Related]

  • 9. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May 01; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Cabebe E, Wakelee H.
    Drugs Today (Barc); 2006 Jun 01; 42(6):387-98. PubMed ID: 16845442
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib.
    Heng DY, Kollmannsberger C.
    Recent Results Cancer Res; 2010 Jun 01; 184():71-82. PubMed ID: 20072832
    [Abstract] [Full Text] [Related]

  • 12. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A.
    J Steroid Biochem Mol Biol; 2008 Feb 01; 108(3-5):261-6. PubMed ID: 17945482
    [Abstract] [Full Text] [Related]

  • 13. The potential role of sunitinib in gastrointestinal cancers other than GIST.
    Grávalos C, Grande E, Gasent JM.
    Crit Rev Oncol Hematol; 2010 Oct 01; 76(1):36-43. PubMed ID: 20133148
    [Abstract] [Full Text] [Related]

  • 14. Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.
    MacIntyre J.
    Clin J Oncol Nurs; 2007 Apr 01; 11(2):237-41. PubMed ID: 17573273
    [Abstract] [Full Text] [Related]

  • 15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 16. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.
    J Oncol Pharm Pract; 2007 Mar 01; 13(1):5-15. PubMed ID: 17621562
    [Abstract] [Full Text] [Related]

  • 17. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug 01; 16(90):138-41. PubMed ID: 17724833
    [Abstract] [Full Text] [Related]

  • 18. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.
    Clin Cancer Res; 2007 Mar 01; 13(5):1367-73. PubMed ID: 17332278
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A.
    Oncologist; 2007 Feb 01; 12(2):191-200. PubMed ID: 17296815
    [Abstract] [Full Text] [Related]

  • 20. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
    Zhu AX, Duda DG, Sahani DV, Jain RK.
    Cancer J; 2009 Feb 01; 15(4):263-8. PubMed ID: 19672141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.